Icosavax Inc

NASDAQ ICVX

Download Data

Icosavax Inc Gross Profit to Fixed Assets Ratio 5 year CAGR for the quarter ending September 30, 2023

Icosavax Inc Gross Profit to Fixed Assets Ratio 5 year CAGR is NA for the quarter ending September 30, 2023. The Gross Profit to Fixed Assets Ratio measures the gross profit generated per dollar of fixed assets (property, plant, and equipment). It indicates how efficiently a company utilizes its fixed assets to generate gross profit. A higher ratio suggests better gross profit generation from fixed assets, indicating improved operational efficiency and potentially higher profitability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Icosavax Inc Gross Profit to Fixed Assets Ratio for the quarter ending September 30, 2021 was 3.33.
NASDAQ: ICVX

Icosavax Inc

CEO Mr. Adam K. Simpson
IPO Date July 29, 2021
Location United States
Headquarters 1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees 60
Sector Healthcare
Industry Biotechnology
Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

FRLN

Freeline Therapeutics Holdings Plc

NA

NA

AVRO

AVROBIO Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email